title: VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
abstract: We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS).We analyzed the medical records of patients with advanced or relapsed STS who had undergone VIP treatment as second-line or more chemotherapy between January 2000 and December 2015. The patients were treated with a combination of etoposide (100 mg/m for 5 days), ifosfamide (2000 mg/m for 2 days), and cisplatin (20 mg/m for 5 days) once every 4 weeks. Treatment response, progression-free survival (PFS), and overall survival (OS) were analyzed in all patients and between responder and nonresponder groups (responders showed a tumor response to any prior systemic chemotherapy before VIP).Twenty-four patients with a median age of 50 years (range: 20-68 years) were treated with VIP. Eleven (45.8%) patients were male and 7 (29.2%) received 2 or more chemotherapy regimens before VIP. Median PFS was 3.7 months (95% confidence interval [CI], 1.3-6.1 months) and median OS was 10.0 months (95% CI, 6.6-13.5). The overall response rate was 37.5%, and the disease control rate was 50%. The responder group showed better PFS (7.7 months vs 3.0 months; P = 0.101) and significantly improved OS (11.0 months vs 8.8 months; P = 0.039) compared to those of nonresponders. All patients reported some grade of hematological toxicity. The most frequently encountered hematological toxicity was neutropenia (any grade, 77.7%; grade 3 or 4, 74.0%).VIP might be effective in patients with previously treated STS.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Moon
authors.forename: Seung-Woo
authors.initials: SW
authors.lastname: Baek
authors.forename: Hyewon
authors.initials: H
authors.lastname: Ryu
authors.forename: Yoon-Seok
authors.initials: YS
authors.lastname: Choi
authors.forename: Ik-Chan
authors.initials: IC
authors.lastname: Song
authors.forename: Hwan-Jung
authors.initials: HJ
authors.lastname: Yun
authors.forename: Deog-Yeon
authors.initials: DY
authors.lastname: Jo
authors.forename: Samyong
authors.initials: S
authors.lastname: Kim
authors.forename: Hyo Jin
authors.initials: HJ
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin; D018572:Disease-Free Survival; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007069:Ifosfamide; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D011034:Podophyllotoxin; D002945:Cisplatin; D007069:Ifosfamide